dv-7028 and Coronary-Thrombosis

dv-7028 has been researched along with Coronary-Thrombosis* in 1 studies

Other Studies

1 other study(ies) available for dv-7028 and Coronary-Thrombosis

ArticleYear
Prevention by DV-7028, a selective 5-HT2 receptor antagonist, of the formation of coronary thrombi in dogs.
    Cardiovascular research, 1991, Volume: 25, Issue:9

    The aim was to determine the role of 5-HT derived from activated platelets in the formation of intracoronary thrombi in dogs.. Canine coronary thrombi were produced by inserting a small catheter filled with collagen powder into the endothelial-injured partially occluded left anterior descending coronary artery. The effects of intravenous DV-7028, a selective 5-HT2 receptor antagonist (bolus of 0.1 mg.kg-1, followed by 0.3 mg.kg-1.h-1 by infusion), and intravenous aspirin (1 mg.kg-1, followed by 3 mg.kg-1.h-1) in this experimental thrombus model were examined.. 43 dogs of either sex were used. In experiment A, DV-7028 (n = 12) or saline (n = 11) was given. In experiment B, aspirin (n = 10) or saline (n = 10) was given.. DV-7028 significantly reduced the formation of coronary thrombi by 51% and attenuated the decrease in coronary blood flow without affecting systemic blood pressure and heart rate. There was a significant relationship between the thrombus weight and the decrease in coronary blood flow (p less than 0.005). Aspirin failed to prevent the formation of coronary thrombi.. The results suggest that 5-HT is involved in the platelet thrombosis and that inhibitory effect of DV-7028, a 5-HT2 receptor antagonist, on coronary thrombus formation was superior to that of aspirin.

    Topics: Animals; Aspirin; Coronary Thrombosis; Disease Models, Animal; Dogs; Drug Administration Schedule; Piperidines; Serotonin Antagonists; Triazines

1991